NCM
CMPX icon

NEXTBio Capital Management’s Compass Therapeutics CMPX Stock Holding History

NEXTBio Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-848,204
Closed -$4.49M – 23
2026
Q1 		$4.49M Sell
848,204
-265,801
-24% -$1.53M 2.08% 17
2025
Q4 		$5.98M Buy
+1,114,005
New +$5.14M 3.51% 12

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NEXTBio Capital Management's CMPX Position: Q2 2026 in Review

NEXTBio Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 848,204 shares — an estimated $4.49M sold.

NEXTBio Capital Management first reported a position in CMPX in Q4 2025 and held it in 2 quarters. The position peaked at $5.98M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • NEXTBio Capital Management reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • NEXTBio Capital Management sold 848,204 Compass Therapeutics shares in Q2 2026, an estimated $4.49M.
  • NEXTBio Capital Management first reported a position in Compass Therapeutics in Q4 2025 and held it in 2 quarters.
  • NEXTBio Capital Management's Compass Therapeutics position peaked at $5.98M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.